Menu Search
Equities

BioMaxima SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
944:FRA

BioMaxima SA

Actions
  • Price (EUR)2.55
  • Today's Change0.01 / 0.39%
  • Shares traded500.00
  • 1 Year change-14.43%
  • Beta0.3380
Data delayed at least 15 minutes, as of Feb 16 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.

  • Revenue in PLN (TTM)60.73m
  • Net income in PLN649.00k
  • Incorporated2008
  • Employees126.00
  • Location
    BioMaxima SAul. Vetterow 5LUBLIN 20-277PolandPOL
  • Phone+48 814408371
  • Fax+48 817442915
  • Websitehttps://biomaxima.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.